← Intellia Therapeutics, Inc. (NTLA) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
Intellia Therapeutics, Inc. (NTLA)
In Vitro & In Vivo Diagnostic Substances · market cap $1.7B · as of 2026-07-16
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-11-05 (est.)
Earnings
Pipeline
4
programs
Upcoming events
4
next 90d+
Dossier
Ready
cached
Intellia Therapeutics (NTLA) is a clinical-stage CRISPR gene-editing company with a ~$1.86B market cap and four pipeline assets across Phase 2/3, led by NTLA-2002 in hereditary angioedema and NTLA-2001 in ATTR cardiomyopathy. The company carries an acutely critical financial position — reported cash of $15.4M representing roughly 0.4 months of runway — making near-term financing a near-certainty before any data readouts materialize. Key Phase 3 catalysts are clustered in H1 2027, including a high-importance nexiguran ziclumeran readout.
The catalyst path
- 2026-11-05 (est.)Earningsimp 5/10
- 2027-01-01Regulatoryimp 6/10
- 2027-06-30Phase 3imp 8/10
- 2027-07-15 (est.)Phase 3 · nexiguran ziclumeranimp 9/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| NTLA-2002 | Phase 3 | Hereditary Angioedema |
| NTLA-2001 | Phase 3 | Transthyretin Amyloidosis (ATTR) With Cardiomyopathy |
| Biological NTLA-2002 | Phase 2 | Hereditary Angioedema |
| nexiguran ziclumeran | Phase 3 | Neuromuscular Disease |
Price & technical context
3-month
-31.0%
6-month
-8.7%
12-month
-29.8%
52-wk range
$8.04–$27.98
vs 50-day MA
+1.1%
vs 200-day MA
-5.6%
Realized vol
99.4%
Max drawdown
-72.6%
Daily closes through 2026-10-01. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for NTLA (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 4 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.